Abstract
Background and objectives
Recent findings from randomized clinical trials indicate an improved patient adherence and blood pressure (BP) control by using fixed-dose combinations (FDCs) in the treatment of hypertension. The aim of the present study was to verify those data in a large real-world sample of hypertensive patients and to cross-check adherence evaluation performed by physicians and patients self-assessment.
Methods
A European multi-center, prospective, 24-week, non-interventional study was conducted including 14,979 patients with essential hypertension and new treatment with olmesartan, amlodipine and hydrochlorothiazide as an FDC. Patients’ adherence was measured using the Morisky Medication Adherence Scale (MMAS-8) and a non-standardized questionnaire was used by physicians and patients for self-assessment.
Results
The mean age of the patients was 63.9 ± 11.78 years and 46.5 % were women. One or more cardiovascular risk factors were present in 71.9 % of patients and 94.7 % had been treated for hypertension before study entry. Mean adherence to medication by MMAS-8 improved from 6.0 to 6.9 at study end. Corresponding improvements of adherence were seen on physicians’ and patients’ self-assessments throughout the study. Mean decrease of systolic/diastolic BP was 26.4/12.8 mmHg without a relevant difference between the MMAS-8 adherence levels. BP target achievement improved from 55.3 to 67.7 % in patients with low versus high adherence. The overall rate of patients with adverse drug reactions was very low (1.76 %) but more frequent in patients with low adherence.
Conclusions
Our data confirm previous clinical trial data on the improvement of medication adherence by switching antihypertensive combination therapy to an FDC and a subsequent improvement in BP target achievement. An observed trend toward a reduction in adverse drug reactions needs to be further investigated in clinical trials.
Similar content being viewed by others
References
Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–9.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task Force M. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–1357
Cowart JB, Taylor AA. Should two-drug initial therapy for hypertension be recommended for all patients? Curr Hypertens Rep. 2012;14:324–32.
Fifth Joint Task Force of the European Society of C, European Association of E, European Association of Percutaneous Cardiovascular I, European Heart Rhythm A, Heart Failure A, European Association for Cardiovascular P, Rehabilitation, European Atherosclerosis S, International Society of Behavioural M, European Stroke O, European Society of H, European Association for the Study of D, European Society of General Practice/Family M, International Diabetes Federation E, European Heart N. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012;19:585–667.
Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag. 2008;4:653–64.
Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlof B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M. Avoiding cardiovascular events through CtiPLwSHI: predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the Accomplish Study. Blood Press. 2008;17:7–17.
Geiger H, Barranco E, Gorostidi M, Taylor A, Zhang X, Xiang Z, Zhang J. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens. 2009;11:324–32.
Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril hcl versus comparable component-based therapy. Congest Heart Fail. 2003;9:324–32.
Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens. 2009;11:475–82.
Izzo JL Jr, Chrysant SG, Kereiakes DJ, Littlejohn Iii T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. 24-hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the Trinity Ambulatory Blood Pressure Substudy. J Clin Hypertens. 2011;13:873–80.
Kereiakes DJ, Chrysant SG, Izzo JL Jr, Littlejohn T 3rd, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J Clin Hypertens. 2012;14:149–57.
Oparil S, Chrysant SG, Melino M, Lee J, Karki S, Heyrman R. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the coach trial. J Hum Hypertens. 2010;24:831–8.
Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the trinity multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:1252–69.
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10:348–54.
Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manage Care. 2009;15:59–66.
Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manage Care Pharm. 2006;12:239–45.
Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563–71.
Hill MN, Miller NH, DeGeest S, American Society of Hypertension Writing Group. Ash position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens. 2010;12:757–64.
Krousel-Wood M, Joyce C, Holt E, Muntner P, Webber LS, Morisky DE, Frohlich ED, Re RN. Predictors of decline in medication adherence: results from the cohort study of medication adherence among older adults. Hypertension. 2011;58:804–10.
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610–8.
Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598–605.
Ferrario CM, Panjabi S, Buzinec P, Swindle JP. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations. Ther Adv Cardiovasc Dis. 2013;7:27–39.
Perreault S, Dragomir A, White M, Lalonde L, Blais L, Berard A. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med. 2009;266:207–18.
Perreault S, Dragomir A, Roy L, White M, Blais L, Lalonde L, Berard A. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol. 2010;69:74–84.
Kettani FZ, Dragomir A, Cote R, Roy L, Berard A, Blais L, Lalonde L, Moreau P, Perreault S. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke J Cereb Circ. 2009;40:213–20.
Prado JC Jr, Kupek E, Mion D Jr. Validity of four indirect methods to measure adherence in primary care hypertensives. J Hum Hypertens. 2007;21:579–84.
Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment: a review. Cardiovasc Diabetol. 2009;8:18.
Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess. 2003;7:1–94.
Esposti LD, Di Martino M, Saragoni S, Sgreccia A, Capone A, Buda S, Esposti ED. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens. 2004;6:76–84.
Hasford J, Schroder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol. 2007;63:1055–61.
Patel BV, Remigio-Baker RA, Mehta D, Thiebaud P, Frech-Tamas F, Preblick R. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens. 2007;9:692–700.
Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a pharmo study. Pharmacoepidemiol Drug Saf. 2005;14:795–803.
Veronesi M, Cicero AF, Prandin MG, Dormi A, Cosentino E, Strocchi E, Borghi C. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag. 2007;3:999–1005.
Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671–81.
Tocci G, Paneni F, Passerini J, Volpe M. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy. Expert Opin Pharmacother. 2012;13:2687–97.
Acknowledgments
The authors acknowledge the cooperation and commitment of all investigators and their staff, who contributed to the trial conduct.
Conflict of interest
PB, RK and RES received consultancy fees, attended advisory boards and have held lectures for a number of pharmaceutical companies including Daiichi Sankyo Germany. WPW and RS are employees of Daiichi Sankyo Germany. EMF is an employee of Daiichi Sankyo Europe, Department for Statistics. CZ has no conflict of interest to declare.
Authors’ contributions
All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data. PB and CZ have drafted the manuscript. The other authors revised the manuscript for important intellectual content and all authors granted final approval of the manuscript to be published.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bramlage, P., Ketelhut, R., Fronk, EM. et al. Clinical Impact of Patient Adherence to a Fixed-Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide. Clin Drug Investig 34, 403–411 (2014). https://doi.org/10.1007/s40261-014-0188-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-014-0188-z